Open AccessDifferent statins produce highly divergent changes in gene expression profiles of human hepatoma cells: a pilot study.
Author(s) -
Agata Leszczynska,
Monika Góra,
Danuta Płochocka,
Grażyna Hoser,
Anna Szkopińska,
Marta Koblowska,
Roksana IwanickaNowicka,
Maciej Kotliński,
Katarzyna Rawa,
Marek Kiliszek,
Beata Burzyńska
Publication year - 2011
Publication title -
acta biochimica polonica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.452
H-Index - 78
eISSN - 1734-154X
pISSN - 0001-527X
DOI - 10.18388/abp.2011_2235
Subject(s) - fluvastatin , simvastatin , atorvastatin , statin , hmg coa reductase , gene , reductase , gene expression , lovastatin , enzyme , pravastatin , pharmacology , biological pathway , biology , bioinformatics , cholesterol , biochemistry
Statins are inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR), the key enzyme of the sterol biosynthesis pathway. Statin therapy is commonly regarded as well tolerated. However, serious adverse effects have also been reported, especially during high-dose statin therapy. The aim of our study was to investigate the effect of statins on gene expression profiles in human hepatoma HepG2 cells using Affymetrix Human Genome U133 Plus 2.0 arrays. Expression of 102, 857 and 1091 genes was changed substantially in HepG2 cells treated with simvastatin, fluvastatin and atorvastatin, respectively. Pathway and gene ontology analysis showed that many of the genes with changed expression levels were involved in a broad range of metabolic processes. The presented data clearly indicate substantial differences between the tested statins.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom